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Abstract
Malignant melanoma is one of the most chemoresistant malignancies in man. 
Although effort is put into developing new drugs to treat metastatic melanoma, still 
dacarbazine, an alkylating agent approved in 1975 for therapeutic use in the USA, is 
considered standard treatment, despite response rates as low as 10%.  
Today, there is no biomarker predicting response to this drug. Therefore, we have 
aimed at identifying such biomarkers and also prognostic markers in metastatic 
melanomas undergoing dacarbazine therapy. 
In the present papers we have revealed that metastatic melanoma patients can be 
classified into 4 different groups according to expression of immuneresponse, 
proliferative, pigmentation, and stromal genes. Most important, these classes have 
significant different overall survival.  
Further, we have identified expression of MGMT, a gene coding for an enzyme 
responsible for repairing DNA damage caused by alkalyting agents like dacarbazine, 
to predict disease stabilisation on dacarbazine treatment and to independently predict 
survival.  
In a gene known to be activated through mutation in melanomas, BRAF, we have 
identified alternative spliced forms where a part of the gene coding for the catalytic 
part of the enzyme is not included, and expression of these alternative spliced forms 
are correlated to response to dacarbazine treatment. In cell culture, knockdown of this 
gene recovered dacarbazine sensitivity in a melanoma cell line wild type (codon 
600V) in BRAF, whereas a mutated cell line (codon 600E) did not respond to this 
knockdown.  
Lastly, we have shown alterations in the p53 pathway to be associated with inferior 
survival. If combined with low p16INK4a expression, the correlation was even 
stronger.  
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1. Introduction
1.1 General remarks 
Malignant melanoma is a cancer type arising from melanocytes, a cell type with 
embryonal neural crest origin, whereas keratinocytes from the skin originates from 
non-neural ectoderm. 91.2% of melanoma diagnosed are skin melanomas, 5.2% 
ocular, 1.3% mucosal and 2.2% of unknown origin (Chang et al., 1998). In rare 
occasions, primary tumours are found in the mucosa from different body compartment 
like intestines (mainly small intestine), sinuses of the face and brain membrane.  
Melanomas on the palms of the hands, under the feet or in the nail beds are classified 
as acral melanomas. Acral melanoma accounts for about 5% of skin melanoma in 
Caucations, but is the predominant form of melanoma in dark skinned (African) 
populations (Thorn et al., 1994). Melanomas can otherwise be found throughout the 
body surface including uvea of the eye and genitals, but mostly on sun-exposed areas. 
Superficial spreading malignant melanomas in general develop from pre-existing nevi 
whereas nodular malignant melanomas develop de novo. Although other skin cancer 
forms like basaliomas and squamous cell carcinoma are more common than 
melanoma, they metastasize infrequent, and therefore melanoma is responsible for 
most skin cancer deaths (Sladden et al., 2009).  
In general, melanocytes detect sun exposure and produce the skin pigment, melanin, 
which they distribute through their dendrites in plasma membrane coated packages 
called melanosomes to surrounding keratonocytes. The melanosomes containing 
melanin form a cap over the nucleus of the keratonocyte to protect its DNA against 
UV light (Figure 1).  
14 
 
Figure 1: Melanosomas containing eumelanin and pheomelanin are produced in the 
soma (body) of the melanocyte. The melanin precursors are oxidated to give darker, 
mature melanin when exposed to UVA light. The melanosomas are transported out to 
the dendrites of the melanocytes and transferred to the keratonocytes where they cover 
the nucleus to protect it against UV light (Park et al., 2009).  
 
1.1.1 Causes of melanoma 
There is a solid body of evidence linking melanoma carcinogenesis to sun exposure 
(Menzies, 2008). However, there are some observations suggesting other etiologic 
agents (unknown) than the total amount of UV radiation. First, about 9% of 
melanomas are non-skin melanomas, which have not been sun-exposed. In addition, 
about 5% are acral melanomas, and here the skin is so thick that UV light will not 
reach the melanocytes of the skin as the melanocytes are located deep in epidermis 
near the basal membrane. Second, the anatomical distribution of malignant melanoma 
does not match the distribution of other sun-related cancers like squamous cell 
carcinoma and total UV dose, but relates more to intermittent sun exposure (Bulliard, 
2000). Third, whereas the incidence of squamous cell cancer continues to rise 
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exponential with age, for melanoma there is not a clear relationship. In the face, the 
incidence rises with age (and sun exposure) as for squamous cell carcinoma, the 
incidence peak is earlier in adult life with respect to other body locations (Rees, 2008). 
The anatomical site of high and low sun exposure predicts the patterns of melanoma 
distribution. The incidence variations between different races tend to follow the risk to 
burn rather than to tan (Cormier et al., 2006). An exception is formation of acral 
melanomas where the aetiology is unknown and the incidence is equal across all ethnic 
groups (Jennifer et al., 2002). There has been a debate whether UV-B alone or in 
combination with UV-A is responsible for cancer initiation, contemporary evidence 
suggests both parts of the UV spectrum are mutagenic (Bennett, 2008). 
1.1.2 Hereditary melanoma 
The most studied locus in inherited melanoma, CDKN2A, is located on chromosome 9 
and code for two distinct proteins, p16INK4A, a tumour suppressor and p14ARF, a protein 
which stabilises the important tumour suppressor, p53 (Greene, 1999). In melanoma 
families, most of the observed mutations in the CDKN2A locus target the p16INK4A 
transcript only. In contrast, only a few families harbour disturbances in the p14ARF 
transcript only (Goldstein et al., 2006).  Similar to Retinoblastoma and Rb mutations, 
germline CDKN2A mutations cause melanoma in a younger age than melanoma 
without inherited disposition. However, the patients are not as young as in 
retinoblastoma, rather young adolescence (Knappskog et al., 2006, 2007). An 
international consortium named GenoMEL (http://www.genomel.org/index.htm) is 
continuously coordinating research in this field and administrates a database for 
registration of different CDKN2A mutations identified 
(http://chromium.liacs.nl/LOVD2/home.php). Although CDKN2A mutations is the 
most frequent cause of inherited melanoma, germline mutations are only found in 25-
50% of melanoma prone families (Goldstein et al., 2007). Genetic testing of melanoma 
prone families is still controversial (Kefford and Mann, 2003). 
CDK4 located on chromosome 12 is another melanoma subspecialty gene. Only a 
few families with inherited melanoma harbour this mutations worldwide, but CDK4 
16 
  
mutations have high penetrance like CDKN2A mutations (Fargnoli et al., 2006). 
Variation in MCIR on chromosome 8 is also related to familial melanoma, but with a 
low penetrance (Bataille, 2003; Höiom et al., 2009; Kennedy et al., 2001).  
 
1.1.3 Clinical features 
A malignant melanoma usually presents as a pigmented lesion. If the lesion is in line 
with the level of the skin, it is called superficial spreading malignant melanoma. A 
lesion that stands up from the skin is called nodular. Lesion in the palms of the hands 
or feet or nail bed it is classified as acral melanoma (Figure 2). The ABCD rule is 
often used to distinguish between a melanoma and a benign nevus by general 
practitioners. The following criteria are used to identify moles that should be further 
investigated:  
 Asymmetrical skin lesion. One half is different from the other half. 
 Border of the lesion is irregular. The edges are notched, uneven or blurred. 
 Colour. Melanomas usually have multiple colours, and shades of brown, tan 
and black are present whereas benign lesions tend to have more homogenous 
colour. 
 Diameter. Pigmented lesions greater than 6 mm are more likely to be 
melanomas than smaller lesions. 
Dermatoscopi is often used by dermatologists to better distinguish benign from 
malignant lesions. When in doubt, the lesion should be excised in toto to allow proper 
diagnosis.  
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Figure 2: Clinical presentation of primary malignant melanomas. Upper left: 
Superficial spreading melanoma, lower left: Nodular spreading melanoma, and right: 
Acral malignant melanoma.  
 
1.1.4 Prognostic factors in melanoma 
The most evident prognostic markers in melanoma are histopathologic and clinical 
aspects like Breslow’s depths, Clark’s level of invasion, mitotic rate, ulceration of the 
tumour, and metastatic tumour load. Many so-called biomarkers are identified in 
melanoma. But in routine clinical practice, only lactate dehydrogenase (LDH) serum 
levels and now also mitotic rate are included. In the current TNM classification 
system, LDH is used to differentiate between M1 b and c because of its prognostic 
value, whereas mitotic rate is used together with ulceration to differentiate between T1 
a and b. (Balch et al., 2009; Balch et al., 2004; Balch et al., 2001b). The melanoma 
marker serum-S100B is also well documented as a prognostic marker (vonSchoultz et 
al., 1996). In the German and Swiss melanoma guidelines, serum-S100B is included in 
the follow of patients with melanoma over 1 mm (Dummer et al., 2005; Garbe et al., 
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2007). A rise in serum value indicates metastatic spread. HMB-45 is an additional 
immune-histochemical marker for melanoma (Skelton et al., 1991), although it is not 
considered as specific as S-100 it is often used as a package together with S-100 in 
diagnosing melanoma (Cochran et al., 1993; Steven et al., 2008). In primary 
melanoma, several biomarkers are identified, but only few are found as independent 
prognostic markers, independent of tumour thickness (Bosserhoff, 2006). These 
include p-AKT, Bcl-2, -Catenin, and HIF2alpha. In metastatic melanoma, Bcl-2 
expression is associated with overall survival (DiVito et al., 2004). 
1.2 Clinical practice
1.2.1 Epidemiology 
The incidence of malignant melanoma has been increasing in western countries for the 
last 5-6 decades (MacKie et al., 2007; Tucker and Goldstein, 2003). The highest 
incidence has been registered in Australia (48/100 000) and New Zealand (31/100 
000). The Norwegian population has the 4th highest incidence in the world (MacKie et 
al., 2009), female: 16.3/100 000 and men: 15.6 /100 000 per year in 2007, an increase 
from 2.1/100 000 (female) and 1.8/100 000 (male) during the period of 1953-1957 
(Cancer Registry of Norway, 2008). The high incidence in Norway (also true for the 
rest of Scandinavia) is believed to be due to a combination of intermittent, high sun 
exposure and fair skin. Lack of sun in Scandinavia during winter time encourage 
people to visit sunny areas to sunbathe without having any pre-existing melanin 
protection in their skin, often leading to sun burns. A similar habit is common among 
Norwegians in the summer time, high sun exposure during a short season. Intermittent 
sun exposure is recognised as a stronger risk factor than chronic sun exposure in 
relation to melanoma development (Elwood and Gallagher, 1998). In the middle aged 
(25-49 years) group of the Norwegian population, melanoma is the second most 
common cancer form after testis cancer in men and breast cancer in women (Cancer 
Registry of Norway, 2008). The same rise in incidence the last 50 years is reported in 
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other cohorts like Scotland (MacKie et al., 2007) and in more dark skinned Caucasians 
in southern and eastern Europe (Vries et al., 2003).  
1.2.2 Staging systems 
The 7th TNM (Tumour, Node and Metastasis) classification was modified in 2009 
(Balch et al., 2009), and includes different prognostic factors (Appendix, Table A1). T 
status is now based on Breslow thickness (se below) and whether there is ulceration or 
not in the tumour. Also, in this version, the mitotic rate is included in the sub-
classification of T1 tumours. N-status is given by the number of nodal metastases and 
N1 is sub-classified whether the node is palpable or is found by histopathological 
examination after Sentinel node biopsy. M status is given after the anatomical 
localisation of the metastases or if serum lactate dehydrogenase level is elevated.  
Clinical (and Pathologic) stage (Balch et al., 2001a) is an even easier system that 
combines different TNM classes into the same groups if the prognosis is similar 
(Appendix, Table A2).  
Breslow’s thickness of the primary tumour was proposed to be a prognostic factor 
by Alexander Breslow in 1970 (Breslow, 1970). This is measured using a micrometer 
on the microscope during histopathologic examination of the primary tumour. Breslow 
was able to show a correlation between tumour thickness and risk of relapse. Tumours 
thinner than 1mm relapsed in rare occasions only, whereas tumours with thickness 
greater than 3.0mm had a recurred in more than half the cases. The invasion level is 
given in mm.  
Clark’s level of invasion was devised by the pathologist Wallace Clark (Clark et al., 
1969) and measures the depth of penetration of a melanoma into the skin according to 
the anatomic layer. The different levels in this system are related to the risk of 
developing metastases (Appendix, Table A3). The reproducibility of this measure is 
not as good as for Breslow’s thickness, and it is no longer included in the current 
TNM classification of melanomas.  
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1.2.3 Established treatment modalities 
Surgery
Generally, treatment of all solid malignant tumours has been surgical excision 
whenever possible. If the cancer has proceeded too far or has metastasised, the term 
inoperable has been used. Still, in some tumour forms, metastatic or locally advanced 
tumours are curable with radiation or chemotherapy (Klimm et al., 2005; Pectasides et 
al., 2009). The surgical treatment of the primary malignant melanoma has changed 
little over the last decades, although a higher awareness of the diagnosis has lead to 
earlier surgical excision (decreased Breslow thickness) of the primary tumour, 
especially in women (MacKie et al., 2007). Partly because of that, and also after large, 
thorough prospective studies (Balch et al., 1993; Lens et al., 2007; Ringborg et al., 
1996; Thomas et al., 2004; Veronesi et al., 1988), with changes in the National 
guidelines,  the excision margins of the primary tumour have decreased causing less 
morbidity and infrequent need for reconstruction at the site of the primary tumour 
(Testori et al., 2009; van Aalst et al., 2003). This is also true for eye melanoma where 
enucleation no longer is the only treatment option for all patients, but local radiation 
can save the eye for patients with limited tumours (Bergman et al., 2005; Chang et al., 
1998; Diener-West et al., 2001). 
Regional lymph nodes are thought to play a role as a barrier for lymphatic cancer 
spread, but new insight and in vitro findings have questioned this hypothesis (David, 
2005). Still, resection of lymph nodes harbouring metastatic spread 
(TLND=therapeutic lymph node dissection) will reduce tumour load, and these lymph 
nodes are available to surgical excision. If the resected metastatic lymph nodes are 
diagnosed with tumour free borders, 30-50 % of the patients will remain relapse-free 
(Allan et al., 2008; Mack, 2004; White et al., 2002). However, there has been no 
prospective, randomized, controlled trial comparing TLND and no treatment. 
Recurrence rate after therapeutic lymphadenectomi is depending mainly on numbers 
of lymph nodes involved but also tumour growth through the lymph node capsule and 
which region that harbours lymph node spread (Mack, 2004; Meyer et al., 2002).  
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Attempts of improving the prognosis by performing a lymph node dissection as 
adjuvant treatment before a lymph node metastasis is clinical diagnosed, so called 
elective lymph node dissection (ELND) have not been able to prove beneficial 
(Cascinelli et al., 1998; Lens et al., 2002).  
In addition to therapeutic lymphadenectomi, sentinel lymph node dissection (SLND) 
has proven to be a strong, independent prognostic indicator, and is now adopted in the 
newest TNM classification (1.2.2). SLND followed by therapeutic lymphadenectomi if 
positive is being evaluated for improving prognosis (Morton et al., 2006).  In this 
method, a radioactive compound and blue dye are injected into the scar where the 
primary tumour was located, and the lymph node(s) that harbour radioactive signal and 
blue dye is dissected and tested for tumour metastases. If metastasis is present, a 
formal lymph node toilette is performed. So far, studies have not been able to prove 
survival benefits for patients receiving SLND compared to controls, but there is a 
significant benefit when looking at time to progression (Testori et al., 2009).  
Patients showing long lasting survival after surgical excision of single metastases are 
few (Frenkel et al., 2009; Leo et al., 2000). Still, surgical excision of metastatic 
deposits may provide palliation for many patients (Essner et al., 2004; Ollila, 2006; 
Testori et al., 2009). New methods like MRI, PET scan and various serum markers for 
detecting distant metastases are being adopted, showing increased sensitivity to 
conventional methods (Holder et al., 1998; Laurent et al.). When these methods are 
used preoperatively for staging patients before surgical excision of what is considered 
to be a single metastasis (diagnosed by screening with conventional methods or 
symptoms), more metastases are often diagnosed, revealing the patient to be 
inoperable.  
Chemotherapy
So far, different regimen of adjuvant chemotherapy has revealed no overall survival or 
relapse-free survival benefits (Eggermont and Gore, 2007) in stage II or stage III 
melanoma.   
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Although dacarbazine (DTIC) was introduced more than 30 years ago and was FDA 
approved in 1976, DTIC monotherapy is still considered standard treatment for 
metastatic melanoma. Further, the response rate is as low as 10-15 % (Eggermont and 
Kirkwood, 2004; Tawbi and Kirkwood, 2007). DTIC is a prodrug, and like the more 
recently approved Temozolomide (TMZ), it is activated to mitozolomide 
(MTIC).Whereas the TMZ is activated in a non-enzymatic degradation process in 
physiological pH, DTIC is activated through oxidative demethylation in cytochrome 
p-450 enzymes (Baker et al., 1999). In vivo, MTIC alkalytes DNA in the O6 position 
of guanine. Methylaled O6 of guanine is mismatched with thymidine. During 
replication, this mismatch is recognized by the mismatch repair system, leading to 
thymidine, and not the methyl group in O6 of guanine, to be removed. Then, the same 
O6metG and T mismatch is gathered, and the mismatch repair system is once more 
activated. This cycling causes secondary lesions and DNA double-strand breaks (Ochs 
and Kaina, 2000), and subsequent activation of apoptotic pathways, mainly p53 
dependent, but also through the intrinsic apoptotic pathway in TP53 mutated tumours 
(Roos et al., 2006).  
23 
Figure 3: A model of O6MeG-triggered apoptosis in p53 wild-type and p53 mutated 
glioma cells (Roos et al., 2006). 
 
DTIC requires activation in the liver (Tsang et al., 1991) whereas TMZ is metabolized 
to mitozolomide in peripheral blood at physiological pH (Villano et al., 2009). TMZ, 
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unlike DTIC crosses blood-brain barrier (Agarwala and Kirkwood, 1998). In addition 
to a more convenient 4-weekly oral application, this drug is also suitable for treatment 
of brain metastases (Villano et al., 2009).  
Combination of drugs in addition to DTIC has not proven superiority to DTIC alone 
(Chapman et al., 1999; Keilholz et al., 2005; Lui et al., 2007). The “Darthmouth” 
regimen was regimen contained different chemotherapeutics (DTIC, carmustine, 
cisplatin and tamoxifen). Although promising results were observed in phase II trials, 
no significant benefit as compared to DTIC treatment was shown in a large phase III 
trial (Chapman et al., 1999). Notably, novel drugs, like taxanes, have not provided 
therapeutic benefits (Eggermont and Kirkwood, 2004; Hodi et al., 2002; Lui et al., 
2007). 
Table 5: Success rates, response odds ratios from studies with dacarbazine 
monotherapy as reference (Lui et al., 2007). 
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Comparators  Author  Year Complete + Partial response Odds
(resp
onse) 
95% 
Confidence 
limits
(response)
All treatments 
with or without 
dacarbazine
  Comparator  DTIC     
   Succes
ses
Failu
res
Succes
ses
Failu
res
Ratio Low
er
Upp
er
Fotemustine Avril et al 2004 17 95 8 109 2.44 1.01 5.90 
Dacarbazine 
interferon  
Bajetta et al 1994 40 138 16 72 1.30 0.68 2.49 
Carmustine 
vincristine 
Bellet et al 1976 5 20 7 18 0.64 0.17 2.39 
Vincristine 
lomustine 
dacarbazine 
Carter et al 1976 34 161 8 40 1.06 0.45 2.46 
Dacarbazine  
carmustine  
cisplatin  
tamoxifen 
Chapman et al 1999 20 99 12 109 1.84 0.85 3.95 
Dacarbazine  
detorubicin  
Chauvergne et 
al 
1982 8 14 4 22 3.14 0.79 12.4
3 
Dacarbazine  
carmustine  
cisplatin 
tamoxifen  
Chiarion Sileni 
et al 
2001 10 31 1 18 5.81 0.69 49.1
6 
Dacarbazine  
C. parvum 
dacarbazine 
Clunie et al 1980 6 16 6 21 1.31 0.36 4.84 
Dacarbazine 
carmustine 
Constanza et 
al 
1972 12 65 9 56 1.15 0.45 2.93 
Dacarbazine  
semustine 
Constanza et 
al 
1977 36 238 19 122 0.97 0.53 1.76 
Dacarbazine 
interferon-alpha  
Falkson et al 1991 16 16 6 26 4.33 1.41 13.3
6 
Dacarbazine  
interferon  
Falkson 1995 17 20 7 29 3.52 1.23 10.0
5 
Dacarbazine  
interferon 
tamoxifen 
Falkson et al 1998 39 163 10 59 1.41 0.66 3.01 
Dacarbazine  
C. parvum 
dacarbazine 
Gough et al 1978 4 12 3 17 1.89 0.36 10.0
3 
Vincristine  
nitrosomethylur
ea 
dactinomycin  
Kongoniaa et a 1981 14 44 13 43 1.05 0.44 2.50 
Dacarbazine  
epirubicin  
Lopez et al 1984 4 16 2 20 2.50 0.40 15.4
3 
Vinblastine  Luikart et al 1984 2 19 4 20 0.53 0.09 3.22 
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Radiation
Melanoma has historically been considered to be a radio-resistant malignancy (Doss 
and Memula, 1982; Shuff et al., 2010). The introduction of higher fractions (greater 
than 4 Gy) (Overgaard et al., 1986) has gradually changed this view.  
In the treatment of primary uveal melanoma, radiation alone is also preferable to 
enucleation if the tumour is limited (COMS, 2006). 
In the treatment of primary skin melanoma, there are no randomised trials supporting 
adjuvant treatment radiation of primary melanoma (Testori et al., 2009). However, in 
some situations like desmoplastic primary tumours and mucosal tumours, adjuvant 
therapy is recommended (Temam et al., 2005; Vongtama et al., 2003).  
In the stage III melanoma, many guidelines recommend radiation as adjuvant 
therapy after lymphadenectomi. The recommendations are based on phase II trials 
showing increased loco-regional control (Bonnen et al., 2004; Chang et al., 2006). 
However, the only randomised study published, revealed no benefit from radiation on 
overall survival or disease free survival (Creagan et al., 1978). 
In palliation of ulcerated or painful metastases radiation have been proven beneficial 
(Kirova et al., 1999). Two large retrospective studies have identified radiation dose as 
an independent prognostic factor (Olivier et al., 2007; Seegenschmiedt et al., 1999). In 
the treatment of multiple or solitary brain metastases radiation can give good palliation 
(Grob et al., 1998). Multiple brain metastases are treated with whole brain radiation 
and give symptom relief in 50-70% of the patients (Ellerhorst et al., 2001; Kirova et 
al., 1999) whereas solitary or few (three or less) metastases are treated with 
stereotactic radiosurgery, and give transient local control in 85-90% of patients (Hara 
et al., 2009; Noel et al., 2002). Resent studies also suggest a modest survival benefit 
when stereotactic surgery is used in combination with or instead of whole brain 
radiation on patients with a few brain metastases (Brennum et al., 2002; Majer and 
Samlowski, 2007; Stone et al., 2004). 
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1.2.4 Experimental therapy of metastastic melanomas 
Isolated limb perfusion/isolated liver perfusion 
To save one affected limb with massive loco-regional melanoma relapse from 
amputation a special treatment option exists where the affected limb are given an intra-
arterial high toxic dose of a chemotherapeutic compound (Melfalan), tumour necrosis 
factor and hyperthermia (Kroon and Thompson, 2009). The limb is coupled to a 
heart/lung machine for oxygenation so that the toxic compounds do not reach systemic 
circulation. The treatment has high efficacy on local tumour control, and may be long 
lasting, although the majority of patients eventually die of other metastases (Hayes et 
al., 2007).  
A similar therapy exists for liver metastases (van Etten et al., 2009) where the liver 
is perfused and oxygenated isolated from the body. This treatment can also be 
performed transcutaneously (Jones and Alexander, 2008).  
Immunogenicity and immunotherapy 
There have been some trials with interferon as adjuvant treatment in melanoma 
(Kirkwood et al., 2001; Kirkwood et al., 1996). Although this adjuvant treatment 
became approved in USA, follow up studies have been unable to repeat superiority to 
observation alone (Atkins et al., 2008).  
Malignant melanomas as well as benign nevi are highly immunogenic. Benign nevi 
disappearing after a period of inflammation around the lesion are well known in the 
literature (Zeff et al., 1997). There are also a few case reports of single metastases 
disappearing completely (High et al., 2005), probably because of involvement of the 
immune system. Based on that, there have been several attempts of stimulating the 
immune system by various approaches, like immunisation with vaccines, interferon 
and interleukin (IL-2 and T-Cell activator) treatment. There have also been attempts to 
use IL-2 as monotherapy or in combination with chemotherapeutic drugs 
(biochemotherapy), but these regimes have not demonstrated increased survival 
compared to dacarbazine treatment. Instead, the patients have experienced increased 
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toxicity (Dummer et al., 2006; Ives et al., 2007; Schadendorf et al., 2009). Still, a 
small subgroup of patients can achieve long lasting responses on this therapy 
(Dummer et al., 1995). These treatments are expensive, resource demanding, and 
patients suffer from side effects. Nevertheless, huge efforts are put into development 
and trials with these regimes. One compound, a T-cell activator, Ipilimumab, has 
recently shown prolonged survival in stage III and IV melanomas compared to a more 
general immune activator gp 100 (Hodi et al., 2010; O'Day et al., 2010). 
Targeted therapy 
The lack of efficient chemotherapy for disseminated disease opens for early testing of 
new drugs or drug combinations, i.e. there is no standard second line therapy, the 
threshold for testing new drugs are low after failure to standard therapy (DTIC). In 
targeted therapy a group of patients having a genetic alteration resulting in an 
enzymatic defect or activation in a specific signal pathway are given a specific 
treatment recovering or inhibiting that enzyme. In tumour forms like chronic 
myelogenous leukemia and metastatic renal cancer, targeted therapy has proven 
successful (Druker et al., 2006; Facchini et al., 2009).  
As BRAF and the MAP-kinase pathway is activated in melanoma (Davies et al., 
2002), much of the focus has been on developing anti-BRAF compounds and other 
MAP kinase inhibitors. One of the first anti BRAF compounds, Sorafenib has so far 
not proven effectiveness alone (Eisen et al., 2006) or in combination with other drugs 
(Hauschild et al., 2009). However, new compounds are emerging and promising in 
Phase I and II trials (Kefford et al., 2010; Patel et al., 2010; Smalley, 2010). 
Nevertheless, no targeted therapy has been proven beneficial in Phase III trials (Hersey 
et al., 2009; McDermott et al., 2008).  
Table 4: Examples of trials in melanoma with drugs targeting survival and apoptosis 
(Eberle et al., 2007; Straume et al., 2009; Tawbi and Nimmagadda, 2009) 
29 
  
Drugs  Targets  Phase # Pat Response  Reference  
OSI-774 (Erlotinib) EGFR II 14 1 SDa Sosman and 
Puzanov, 
2006 
Imatinib mesylate BCR-ABL, c-
Kit and 
PDGF-R 
II 26 0 SD Wyman et 
al. 2006 
R115777 (Tipifarnib) Farnesyl 
transferase 
II 14 0 CR Gajewski et 
al. 2006 
Sorafenib B-Raf, Raf-1, 
c-Kit VEGFR 
and PDGFR 
II 37 6 SD Eisen et al. 
2006 
Sorafenib + carboplatin/paclitaxel B-Raf, etc. I/II 35 11 PR, 19 
SD 
Flaherty et 
al. 2004 
Sorafenib + temozolomide B-Raf, etc. II 78 15 PR, 37 
SD 
Amaravadi 
et al. 2007 
Sorafenib + DTIC vs. DTIC B-Raf, etc. II 101 PFS: 21/12 
weeks, 
ORR: 
24%/12% 
McDermott 
et al. 2007 
Sorafenib + carboplatin/paclitaxel 
vs. carboplatin/paclitaxel 
B-Raf, etc. III, 2. 
line 
270 PFS: 18/17 
weeks; 
ORR: 
11%/12% 
Agarwala et 
al. 2007 
Sorafenib + carboplatin/paclitaxel 
vs. carboplatin/paclitaxel 
B-Raf, etc. III, 1. 
line 
 Underway 
(E2603) 
Flaherty 
2007 
Bevacizumab VEGF II 27 5 PR, 5 SD Straume et 
al. 2008 
PD0325901 MEK I/II 27 1 PR, 4 SD Lorusso et 
al. 2005 
Perefosine PKB/Akt II 18 3 SD Ernst et al 
2005 
CCI-779 (Temsirolimus) mTOR II 33 1 PR Margolin et 
al. 2005 
RAD-001 (Everolimus) mTOR II 20 7 SD Rao et al. 
2006 
Oblimersen + DTIC Bcl-2 I/II 14 1 CR, 2 
PR, 3 MR 
Jansen et al. 
2000 
Oblimersen + DTIC (1) vs. DTIC 
(2) 
Bcl-2 III 386, 
385 
52 OR (1), 
29 OR (2) 
Bedikian et 
al. 2006 
Bortezomib (PS-341) Proteasome, 
NF-B 
II 27 6 SD Markovic et 
al. 2005 
Bortezomib (PS-
341) + Temozolomide 
Proteasome, 
NF-B 
I 19 3 MR, 1 PR Sosman and 
Puzanov 
2006 
Bevacizumab+/-INF2b VEGF II 16/16 5/3 SD Varker et al. 
2007 
Bevacizumab, carboplating  and 
paclitaxel 
VEGF II 53 9 PR, 30 
SD 
Perez DG et 
al. 2009 
Thalidomide + DTIC  VEGF and 
other 
II 13 1 PR, 3 SD Ott PA et al. 
2009 
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 a Abbreviations: OR, objective response; ORR, objective response rate (median); PR, 
partial response; CR, complete remission; MR, moderate regression; CR, clinical 
response; SD, stable disease; PFS, progression-free survival (median).  
1.3 Molecular Biology of malignant melanoma 
1.3.1 Genetic alterations leading to cancer development 
“The two hit theory” was described by Alfred Knudson (Knudson, 1971) when he 
published a statistical analysis of retinoblastoma in children. In this disease inherited 
cases got the disease at young age as compared to spontaneous case. Also, affected 
children frequently got the tumour in both eyes. The findings were consistent with 
“two hit” events, and later the retinoblastoma gene (Rb) was found as a tumour 
suppressor gene (Hong et al., 1989). In inherited cases of retinoblastoma, patients 
receive one mutated allele of the Rb locus and later acquire another hit (mutation or 
loss of heterozyozity) on the other allele, thus no Rb tumour suppressor with 
biological function is left. The Rb protein is central in the “Rb pathway”, one of the 
most important pathways regulating cell cycle (Massague, 2004). The “two hit” theory 
is applicable to all tumour suppressors. If one allele is mutated, still, there is a protein 
with biologic function transcribed and translated from the other allele. Therefore, the 
second allele has to be altered in some way so that biological function is reduced 
before carcinogenesis can be initiated. 
In 1969 Frederick Li and Joseph Fraumeni identified early onset of different soft 
tissue cancers in siblings and cousins (Li and Fraumeni, 1969). This syndrome was 
later named Li-Fraumeni cancer syndrome, and years later, in 1990, germline 
mutations in the already known tumour suppressor p53 was identified in all family 
members suffering from this syndrome (Malkin et al., 1990).  
For p53, unlike classic tumour suppressors, a mutant type of the protein translated 
from one allele can inhibit function of the protein from the normal allele by 
interference with the hetero-tetramer of the protein, probably driving the wild type 
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proteins into a mutant type of conformation in this structure (Dridi et al., 2006; 
Ishimaru et al., 2003; Willis et al., 2004). Tumour suppressors normally have a 
negative control over cell cycle or promote apoptosis.  
Oncogenes, on the other hand, are genes that, when mutated, code for proteins which 
gain another or stronger biological function and promote carcinogenesis. Mutation in 
one allele is sufficient. As for tumour suppressors, in addition to activation of an 
oncogene, an additional step is often required for cancer to occur. This step can be 
mutation in other genes, environmental factors or viral infections. The first oncogene 
to be discovered was the v-src (viral sarcoma), a viral gene which causes sarcoma in 
chicken (Tal et al., 1977). A similar gene in human cell (c-src) was later found 
(Oppermann et al., 1979), and this gene is activated by a mutation. Proto-oncogenes 
are genes that do not need mutation to be activated, but through overexpression or 
duplication their normal function is enhanced (Pall, 1981). Oncogenes often code for 
proteins involved signal transduction pathways important for cell growth, examples 
are RAS and ERK (Fang and Richardson, 2005; Sivaraman et al., 1997).  
Gene alterations can occur at several levels in the transcription - translation process 
to mature protein, and a brief overview of the normal function of a gene is given. A 
gene locus has coding (exons) and non coding (introns) areas (Sharp, 1985). When a 
gene is transcribed, a pre-mRNA is first produced containing both exon and introns, 
secondly introns are removed by a process called splicing (Berget et al., 1977). Then, 
the mRNA is translated to a protein (Söll et al., 1965). There are possibilities for 
introduction of aberrations on all levels listed here, and in several control levels in 
between. At the chromosomal level, gross deletions, duplications, translocations, or 
inversions are well known, giving hereditary syndromes like Down’s syndrome and cri 
du chat (Lejeune et al., 1959; Lejeune et al., 1964). Although one would expect all 
expressed genes on chromosome 21 to be over-expressed, expression studies have 
revealed that only 20% of the genes are in fact over-expressed, the later 80% are 
compensated for through regulatory mechanisms (Ait Yahya-Graison et al., 2007).  
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Figure 4: Different types of gene mutations and mechanism of epigenetic silencing 
(Lonning, 2007). 
 
On the DNA level the same errors can occur. Again, deletions, mutations, and 
insertions are possible (Fig 4). The transcription and translation process are regulated 
on many levels, and dys-regulation results in high (over-expression) or low (silencing) 
mRNA or protein levels. Lastly, proteins are modified after translation by addition for 
functional groups like acetate, phosphate, lipids and carbohydrates, or structural 
changes by introduction of disulfide bridges in the protein (Burnett and Kennedy, 
1954; Fleischer, 1983; Polevoda and Sherman, 2003; Sevier and Kaiser, 2002), Figure 
5. Amino acids can also be removed inside the protein or at the end. When insulin is 
synthesised, pro-insulin is first produced in the cell. Then a polypeptide is removed 
after the introduction of disulfide bonds giving mature insulin (Massague et al., 1981). 
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Phosphorylation is a normal mechanism for controlling enzyme function, turning the 
enzyme on and off (Hurley et al., 1990). The transcription process is also regulated by 
different mechanisms including interaction of trans and cis acting factors. A trans 
acting transcription factors is a DNA sequence or a gene that code for a protein or 
siRNA that regulate transcription of the target gene. A cis acting factor is a DNA 
sequence usually located at the 5’ end of the coding region, but can also in a intron or 
3’ end of the coding region that bind trans acting factors. Silencing of genes through 
promoter methylation (Kass et al., 1997), interaction of transcription factors at the 
promoter (Mitchell and Tjian, 1989), and histone acetylation (DNA packing) (Elgin, 
1996) have been explored, whereas mechanisms responsible for silencing of the extra 
X chromosome in women include all these mechanisms and are incomplete understood 
(Minks and Brown, 2009).  mRNA splicing is regulated by splicosome assembly and 
splicing factors (Chen and Manley, 2009) and translation is inhibited by siRNA and 
other decay mechanisms of mRNA (Matzke et al., 2001). Mechanisms for controlling 
protein processing are less studied than gene transcription and translation, and 
proteomics is a relative new, but promising cancer research field. 
 
Figure 5. Post-translational modifications of human p53. Specific residues are 
modified as shown, with phosphorylation (P) in orange, acetylation (A) in green, 
ubiquitylation (Ub) in purple, neddylation (N) in pink, methylation (M) in blue and 
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sumoylation (SU) in brown. Proteins responsible for these modifications are shown in 
matching colours (Toledo and Wahl, 2006). 
 
1.3.2 Epigenetic changes 
In addition to genetic changes affecting cancer development, there is an emerging 
knowledge of DNA information outside the human 30 000 genes. The term 
epigenetics refers to study of heritable changes that can not be explained by changes in 
DNA sequence (Bird, 2007). The most studied epigenetic changes are histone 
modification and promoter methylation (Cheung and Lau, 2005).  
DNA is wrapped around proteins which are called histones. Histones are responsible 
for further condensation of DNA. In its highest condensed form, DNA is not 
accessible for gene transcription, and modification of these histones like methylation, 
acetylation and phosphorylation regulates the tightness of this wrapping and thereby 
transcription (Strahl and Allis, 2000). During mitosis, these protein modifications are 
thought to be inherited into its daughter cells and several models exists for explaining 
this inheritance in the replication fork, however in some situations a faithful 
replication is not always desired, and therefore there is a window for change during 
mitosis  (Probst et al., 2009). Also, modification of histones is a continuous process by 
different enzymes which active regulate gene transcription (Shilatifard, 2006).  
The second epigenetic regulation mechanism is methylation at CpG sites. Here, 
cytosines are converted into 5-methylcytosine. 5-methylcytosine is not recognised by 
the transcription apparatus, and when this occurs in the DNA promoter, the gene is 
turned off (Siegfried et al., 1999), Figure 4. DNA methylation is regulated by several 
enzymes, and methylation and demethylation is believed to be a continuous process 
(Kangaspeska et al., 2008). DNA methylation is the most studied of the two epigenetic 
regulation mechanisms. Promoter methylation is closely related to cancer by silencing 
of tumour suppressors in cancer development (Esteller, 2008; Kanai, 2008), and assays 
identifying promoter methylation has been designed for several tumour suppressor 
genes.  
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1.3.3 Alternative splicing 
Alternative mRNA splicing is found in more than half of multi exon genes (Johnson et 
al., 2003), and alternative splicing is responsible for increasing the functional diversity 
of the human genome in making isoforms of the protein (Stamm et al., 2005). 
Although the function of alternative splicing driving cells into a cancer phenotype is 
not completely understood (Keren et al., 2010), alternative splicing is regulated 
through expression of enhancers or silencers with important functions in the 
splicosome assembly or by activation of splice specific transcriptor factors (House and 
Lynch, 2008). The splicing factor 2/alternative  splicing factor (SF2/ASF) has been 
identified as a proto-oncogene and is upregulated in various tumours stimulating 
alternative splicing by antagonising the inhibition of heterogenous nuclear 
ribonucleoprotein (hnRNP) family on splicosome assembly (Karni et al., 2007). 
Alternative splicing has been identified in tumour suppressors like BRCA1/2 
(Gutierrez-Enriquez et al., 2009), APC (De Rosa et al., 2007), CHK2 (Staalesen et al., 
2004), TP53 and TP73 (Hofstetter et al., 2010) with inactivation of the genes as a 
result and susceptibility to cancer, both inherited and sporadic, has been reported 
(Venables, 2004). Alternative splicing has been explored both on high throughput 
platforms including all known genes and on a single gene level, and this will hopefully 
provide new diagnostic and therapeutic tools in cancer treatment in the future (Pajares 
et al., 2007).  
1.3.4 Cancer stem cells 
The models for cancer stem cells were first introduced in hematopoietic cancers in 
1997 (Bonnet and Dick, 1997), but the concept has later been applied to the field of 
solid tumours. The hypothesis is that a malignancy is created from pluripotent cells 
like ordinary stem cells, which have the ability to differentiate into all cell types. 
Cancer treatment with traditional chemotherapy will only kill differentiated tumour 
cells, but the cancer stem cell will survive and cause relapses later on (Woodward et 
al., 2005). Therefore, according to this model, a successful cancer treatment will have 
to include a specific cancer stem cell therapy. They postulate that after specific cancer 
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stem cell treatment, the tumour will regress just by lack of growth stimuli from the 
cancer stem cell.  
Investigators have been able to isolate melanoma cells with some stem cell 
characteristics, but they have not been able to conclude that these cells are in fact 
cancer stem cells (Dou et al., 2007; Na et al., 2009). Also, whether melanoma stem 
cells are derived from melanocyte stem cells, melanocyte progenitors or de-
differentiated melanocytes remains unclear (Zabierowski and Herlyn, 2008). 
1.3.5 Important signal transduction pathways with disturbances in 
melanoma
Cell cycle 
Because of p16’s importance both in inherited melanoma and as a prognostic factor in 
primary melanoma, a brief overview of cell cycle is presented. The cell cycle consists 
of four faces, M (mitosis), G1, G2 and S (synthesis) phase. The two G (gap) phases 
allow repair of DNA. G1, S and G2 are called interfaces. A cell passage through the 
cell cycle is thoroughly regulated by different proteins called cyclins. These proteins 
have different associated proteins called cyclin dependent kinases (CDKs). The 
concentration of the different cyclins and their associated kinases rises and falls during 
cell cycle, and these complexes drive the cell through the cell cycle (Massague, 2004). 
In G1, G2 and M, there are cell cycle checkpoints which control cell cycle. Different 
biochemical signalling pathways converge at these checkpoints and stop cell cycle if 
the genome is damaged. Stimuli to the first checkpoint (G1) like response to DNA 
damage leads to arrest of cell cycle. The next checkpoint, the G2 checkpoint, also has 
an effect on cycle in response to DNA damage or unreplicated DNA (Nyberg et al., 
2002). This ensures that damaged DNA is not replicated during S-phase. Finally, the 
M-checkpoint reacts on misalignment on the mitotic spindle and arrest chromosomal 
segregation (Malmanche et al., 2006). Disruption of these checkpoints allows new 
mutations to be integrated in the genome, mutations that for instance may induce 
carcinogenesis.  
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The G1 checkpoint is the best characterised of these checkpoints. Many signalling 
pathways intervene here on the basis on metabolic status, stress and gene status, and a 
decision is made regarding self renewal, differentiation and death. In order to continue 
with cell cycle, different Cyclin/Cyclin dependent kinase (CDK) - complex has to be 
activated. For G1, the CDK includes CDK2 which combines with Cyclin E and 
activate a pre-replicative complex (PRC). Activated PRC recruits DNA helicases, 
primases and polymerases causing unwinding of DNA helix and DNA replication. 
Newly synthesised DNA cannot reassemble new PRC until CDK activity drops at the 
end of the mitosis ensuring that DNA is only replicated once (Prasanth et al., 2004). 
The level of Cyclin E is constant high in early embryos allowing CDK2 to initiate S-
phase as soon as the M-phase is over (Murray, 2004). In most other cells, however, the 
levels of Cyclin E are low until mitotic signal intervene. Cyclin E expression is under 
control of E2F transcription factor. E2F is bound to the retinoblastoma protein (Rb), 
and Rb binding turns the transcriptor factor into a repressor. Mitotic stimuli increases 
the levels of Cyclin D which combine with its CDK (CDK 4 and 6), and this dimer 
phosphorylates Rb so that E2F dissociate from Rb. As a consequence, E2F becomes 
active and can support transcription of Cyclin E. Cyclin E-CDK2 complex also 
phosphorylates Rb causing a positive feedback loop ensuring S-phase entry once 
CDK2 has been activated. Research done on mice deficient of Cyclin D show that 
some tissues are strictly Cyclin D dependent like hematopoietic tissue whereas other 
tissues are Cyclin D independent (Kozar et al., 2004).  
CDKs are also regulated by direct binding by inhibitory proteins which combine 
with the Cyclin/CDK complex and disrupt its catalytic centre. Many of these proteins, 
p15, p16INK4a and p57 are mediators of cytostatic signals. Another inhibitory protein, 
p21 is a downstream protein of p53 in the p53 cascade (Gil and Peters, 2006). Another 
inhibitor that binds to the Cyclin-CDK complex is p27. Mitogenic signals like 
CDK4/6 neutralise p27 together with its effect on Rb so that CDK2 is activated both 
through transcription and removal of the inhibitory protein p27. When the cell balance 
tips towards CDK2 activation, CDK2 bites back at p27 by phosphorylating the protein 
and marks it for polyubiquitination and destruction (Montagnoli et al., 1999).   
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As mentioned above, p16INK4a is another inhibitor of Cyclin-CDK complex (Sherr, 
1996). p16INK4a expression is induced by transcripton factors in response to excess 
RAS-MEK-ERK activity, thereby protecting cells against hyperactive RAS pathway 
inducing senescence by blocking CDK4/6 activity (Serrano et al., 1997). 
 
 
Figure 6: The Rb pathway 
RAS-RAF-MEK-ERK (MAPK) pathway 
Activation of the growth kinase pathway, MAPK, has been proven in several tumour 
forms, but is predominant in melanoma with activated BRAF V600E in 50-70% of 
melanoma cell lines, and additional 10-20% of NRAS in codon 61 (Davies et al., 
2002), and great effort are put into identifying and testing molecules targeting this 
pathway specific by the pharmaceutical industry. This signal transduction pathway 
couples binding of growth factors at the cell membrane to intracellular response 
(Figure 7). Upon EGF receptor activation by EGF, two molecules of EGFR are 
dimerised, and their intracellular parts are autophosphorylated. Grb2 and SOS (sons of 
sevenless) are recruited to EGFR’s intracellular domain, and RAS is translocated from 
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cytosol to the cell membrane. RAS is activated by GTP binding, and RAF is activated 
by phosphorylation. RAF phosphorylates MEK which again phosphorylates ERK 
(Schlessinger, 2000). ERK enters the nucleus and activates different transcription 
factors like C-MYC and AP1 by phosphorylation (Karin, 1995; Marampon et al., 
2006). AP1 binds to the Cyclin D gene and facilitates its transcription whereas C-Myc 
targets p53. (Hennigan and Stambrook, 2001; Reisman et al., 1993). Thereby, 
activation of this pathway by EGF results in Cyclin D expression and facilitates cell 
cycle progression. 
PIP2-AKT pathway is another downstream pathway of RAS. Activated RAS can 
recruit membrane bound Phosphatidylinositol 3-kinase (PI3K), and 
phosphatidyllinositol-4,5-bisphosphate (PIP2) is phosphorylated to PIP3. PIP3 recruits 
two serine/threonine kinases to the membrane, PDK-1 and AKT. Here PDK-1 
phosphorylates AKT, and AKT translocates to the nucleus where it phosphorylates 
different transcriptor factors and also proteins that are involved in apoptotic and 
survival pathways (Franke et al., 1997). In relation to cell cycle AKT inhibits glycogen 
synthase kinase 3-, preventing this kinase from phosphorylating and destabilising 
Cyclin D (Sears and Nevins, 2002). AKT also inhibits FOXO transcription factors by 
barring them from the nucleus and thereby prevent transcription of its gene targets like 
p27 and p21 (Arden, 2004; Brunet et al., 1999; Medema et al., 2000).  
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Figure 7: The MAPK pathway 
1.4 Chemoresistance in melanoma 
1.4.1 The p53 pathway 
  
Unlike other cancer forms (Toledo and Wahl, 2006), melanoma has a low frequency of 
TP53 mutations (Akslen et al., 1998; Florenes et al., 1994). This conclusion was 
supported by studies where p53 was analysed by immunhistochemistry and 
sequencing of known hot spot exons. The open reading frame of TP53 was not 
sequenced. Still, biallelic deletions and inactivation of the p14ARF transcript of 
CDKN2a gene, coding for a protein binding and inactivating MDM2 and thereby 
stabilising p53, are frequent in melanoma (Grafstrom et al., 2005). One of the aims of 
this study was to see if such mechanism could be involved in chemoresistance in this 
cohort. Radiation and some cytotoxic drugs, antracyclins like Doxorubicin and 
Epirubicin, cause double stranded DNA breaks and exert their effect through the p53 
pathway (Figure 8): When a DNA double-stranded DNA break is sensed by ataxia 
teleangiaectasia mutated (ATM), ATM phosphorylates and activates the tranducer 
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checkpoint kinase, CHK2, which again signals through p53. Both ATM and CHK2 
phosphorylyse MDM2 (and p53) so that MDM2’s inhibitory effect of p53 is disrupted. 
p53 is a transcriptional factor for many different downstream effectors, amongst them, 
p21. Upon DNA damage, p53 is activated and p53 induces p21 transcription. p21 
inhibits cell cycle by binding to the Cyclin-CDK complex (see 1.3.5).  
Resistance to alkalyting agents like DTIC has been linked to expression of the DNA 
repair enzyme MGMT (see 1.4.2). No alternative pathway has been identified as 
responsible for the primary resistance to anti neoplastic drugs in melanoma. 
 
Figure 8: The p53 pathway 
1.4.2 O-methylguanine-DNA methyltransferase 
  
MTIC, the active compound of DTIC and temozolomide adds methyl groups to 
several localisations in DNA, among them N7 position of guanine and O6 position of 
guanine (Denny et al., 1994; Middleton and Margison, 2003). Although methylation of 
the O6 position of guanine is the less common event of these, it is believed to be of 
most importance (Friedman et al., 2000). The DNA repair enzyme O-methylguanine-
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DNA methyltransferase (MGMT) reverses this reaction and thereby inhibits the killing 
of cancer cells by removing drug induced methyl group of guanine (Graves et al., 
1989; Souliotis et al., 1991). Hence, the DNA damage will not be recognised by the 
cell, and no apoptosis will occur. Tumour expression of this enzyme is recognised as a 
major contributor to resistance to alkalyting agents in vitro (Scudiero et al., 1984), but 
the correlation has not been so evident in clinical trials. Hypermethylation analysis of 
MGMT has been shown to correlate with positive clinical response to temozolomide in 
gliomas (Esteller et al., 2000; Hegi et al., 2004; Paz et al., 2004). Also, a report in 
2002 showed a trend correlating MGMT immunostaing to DTIC response in 
melanoma, although not significant (Ma et al., 2002). Recently, a paper found a 
correlation between expression of MGMT and temozolomide response in melanoma 
cell culture (Augustine et al., 2009). Interestingly, the authors were unable to find a 
correlation to methylation of the MGMT promoter, suggesting other regulating 
mechanism than methylation of the promoter to be of importance for MGMT 
expression. Clinical trials using other substrates for MGMT (i.e. inhibiting the 
enzyme) in combination with alkalyting agents have been performed. They have 
shown efficacy in reducing MGMT activity, but so far not on clinical outcome (Quinn 
et al., 2009; Watson et al., 2009).  
1.4.3 Predictive factors in melanoma 
Regarding predictors of therapy, there are no such for standard treatment. A 
combination of BRAF mutational status and CDKN2A expression has been identified 
as predictors in isolated limb perfusion with high dose melphalan and actinomycin D 
(Gallagher et al., 2008). Also MGMT expression has been linked to temozolomide 
cytotoxisity in melanoma cell lines (Augustine et al., 2009) but so far not in vivo.  
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2. Aim of study 
The primary aim of this project was to identify predictive factors in relation to 
dacarbazine treatment in metastatic melanoma. Secondly, we wanted to identify 
molecular factors predicting survival in patients suffering from metastatic melanomas. 
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3. Material and methods 
3.1 Patients
From year 1999 and onwards, 85 consecutive patients referred for metastatic 
malignant melanomas to the Department of Oncology, Haukeland University 
Hospital were included in the study. The last follow up was May 2009. All patients 
were given information about the study and signed an informed consent form.  
For paper I, 57 patients of the total material were included in the main study. 
Initially, we excluded 28 patients having tumour samples obtained by Tru-cut biopsy 
from this study due to a limited amount of tissue available. Subsequent, tissue from 
20 out of these 28 were analysed in the second part of the microarray as a validation 
set.   
3.2 Therapeutic protocol 
The protocol for this study was designed by the authors JG and PEL, and the protocol 
was approved by the regional ethic committee. The patients were preferably treated 
with dacarbazine (DTIC 800-1000mg/m2 every 21 days), but also a related drug, 
Temozolomide. This drug is converted to the same active substance as DTIC, MTIC. 
Temozolomide was given to a few patients with advanced disease complicated by 
brain metastases.  
Clinical responses to be used for the present thesis were evaluated retrospective 
after the UICC-criteria every 6 weeks by CB in collaboration with the medical 
oncologist JG.  
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3.3 Tissue sampling 
Surgical biopsies from accessible lymph nodes and subcutaneous metastases were 
obtained the day before implementing the first chemotherapy cycle. For patients with 
metastases to internal organs biopsies were obtained under ultrasound guidance with 
a Tru-cut biopsy needle. For most of the patients, Tru-cut biopsies were obtained on 
the day after treatment and whenever therapy was changed due to disease 
progression. This was done to look at molecular changes caused by the therapy and 
disease progression, but these samples have not been analysed as a part of this thesis. 
A part of the biopsy was examined histopathological to make sure that the sample 
was representative, and indeed some of the samples had to be rejected as expected for 
the study (6 patients). The rest of the sample was snap frozen in liquid nitrogen until 
examination to conserve RNA. 
3.4 Nucleic acid purification 
RNA was extracted with Trizol® reagent (Invitrogen, Carlsbad, CA) according to the 
manufacturer’s instructions. Some of the samples were contaminated with melanin 
after the RNA extraction, and further steps had to be added to separate RNA from 
melanin (Carninci and Hayashizaki, 1999). Finally, RNA was dissolved in H2O and 
kept in -80oC.  
DNA was extracted from the biopsies using QIAamp DNA Mini Kit® (Quiagen, 
Venlo, The Netherlands). Also for the DNA analyses, some of the samples had to 
undergo further steps to remove melanin (Lagonigro et al., 2004; Nozawa et al., 
1999). Isolated DNA was dissolved in H2O and kept in -20oC.  
Complementary DNA (cDNA) was synthesised using reverse transcriptase (Roche 
diagnostics, Basel, Switzerland) following the manufacturer’s instructions, and oligo 
dT was used as transcriptase primer. For the lightcycler assays, the cDNA was made 
from the same RNA concentration, and random hexamers was added to the solution 
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to standardise the quantity of the cDNA in the whole open reading frame. Three 
parallel cDNA preparations were made for combined analyses.  
3.5 PCR
For mutation screening of the tumour samples, we used cDNA as a template and 
performed PCR’s up to 500bp of the open reading frame. For some genes we had to 
use nested PCR to amplify the product, in others, we had to use DNA as template and 
amplify all exons. The amplification was performed with the DyNazyme EXT 
polymerase system (FINNZYMES, Espoo, Finland). Another polymerase (AmpliTaq 
Gold™ DNA polymerase, Roche Diagnostics, Basel, Switzerland) was used for 
selected genes like BRAF. 
3.5.1 Methylation specific PCR (MSP) 
To determine the methylation status of the promoters of interest, we used primer and 
annealing temperatures as published previously by others. We used Ez DNA-
methylation gold ™ Kit (Zymo Research, Orange, CA) for the bisulfide conversion 
of tumour DNA. PCRs were performed with specific methylated or unmethylated 
primers for the promoter, and in the methylation specific PCRs we also used 
AmpliTaq Gold™ DNA polymerase for the amplification. Promoter status was 
determened after gel electrophoresis of the PCR products on a 3% agarose gel stained 
with ethidiumbromide. A CpGenome™ Universal Methylated DNA (Cemicon 
International, Temacula CA) was used as a positive standard and leukocyte DNA 
from healthy volunteers as negative control.   
3.5.2 Quantitave Real Time PCR (qRT PCR) 
A duplex qRT-PCR system (LighCycler®480, Roche Diagnostics, Basel, 
Switzerland) was used in the following concentrations: 1x LightCycler ® 480 Probes 
Master, 0.5μM primers, and 0.125μM probes. In addition, 2μl template was added 
the mixture in a final volume of 20μl. The cDNA was made from total RNA, in a 
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50ng/μl concentration. A housekeeping gene, -2-microglobulin (B2M) served as a 
standard and was used as expression reference in each sample. Expression levels 
were presented as percentage of expression in the cell line SK-Mel 28. All qRT PCR 
assays were performed in three parallels.  
3.5.3 Radioactive Quantitative PCR 
For the analyses of the alternative BRAF splices we were not able to design a specific 
qRT-PCR because of resemblance in sequence at the breaking points. Therefore, we 
were forced to use a method with radioactive -32P-dCTP in the PCR and quantify the 
amount of the different splices based on radioactive count in different bands after gel 
electrophoresis and transfer of the products to a membrane. 
3.6 Multiplex Ligation-dependent Probe Amplification 
(MLPA)
MLPA is a multiplex PCR method used to detect abnormal copy number of multiple 
genes or parts of genes down to 50-70 base-pairs. Primers and probes are designed to 
numerous sites on the locus of interest and also to other places on the same and 
different chromosomes for normalisation. Contrasting other PCR’s it is not the 
primers that hybridise to the locus, but two adjacent MLPA probes that again are 
ligated. If the sequence is missing, no ligation will occur, with no subsequent 
amplification. The primers are marked with fluorescence and more amplification will 
give a higher fluorescence. For each target sequence, the distance between the two 
primers are unique and therefore the different targets can be discriminated by 
electrophoresis, and fluorescence intensity for each target is compared that of a 
standard.    
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3.7 Cell culturing 
In the in vitro assay described in paper III two different melanoma cell lines were 
cultured, SK-mel 28 as a standard cell line mutated in BRAF, codon 600 and SbCl2 
one of the few available melanoma cell lines wt for BRAF codon 600 and NRAS 
codon 61. These cell lines were cultured in RPMI 1640 (Carlsbad, CA, USA) added 
10% foetal bovine serum (FBS) and L-glutamine. Incubation conditions were 370C, 
5% CO2 and 100% humidity.  
3.8 Western blot 
Western blots were performed as previously described (Lyustikman et al., 2008). 
Briefly, the cells were lysed, and the cytosolic fraction loaded on a SDS-page gel for 
electrophoresis. The protein was then transferred to a nitrocellulose membrane and 
probed with monoclonal or polyclonal antibody specific to the target protein. A 
secondary antibody tagged with horseradish peroxidase was then added, and 
following incubation, a chemiluminescent substrate was added and the light detected 
on a photographic film.  
3.9 Small interfering RNA (siRNA) knockdown 
The cells were cultured on a dish over night and transfected with siRNA against the 
target gene according to the manufacturer’s instruction using transfection reagent 
from Dharmacon (Lafayette, CO, USA). After incubating the cells for 48 hours, 
siRNA knockdown was considered most effective, and the cells were incubated with 
dacarbazine or control. 
3.10 aCGH
Sample DNA and pooled reference DNA (Promega, Madison, WI, USA) was 
labelled and washed as described (Jonsson et al., 2007) and hybridised to 32k tiling 
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resolution BAC clone microarrays produced at the SCIBLU Genomics Centre, Lund 
University (www.lth.se/sciblu) as previously described (Jonsson et al., 2007). Median 
background-corrected intensities were filtered to remove spots that had been flagged 
in the image analysis or had a signal-to-noise ratio <5 in either of the intensity 
channels. Normalisation was performed as described (Staaf et al., 2007). Using 
estimated noise in each array, a moving average was applied to define adaptive 
thresholds for each sample (Staaf et al., 2007), subsequently used to call gains and 
losses by the CGH-Plotter segmentation algorithm (Autio et al., 2003). Fraction of 
the genome altered (FGA) was calculated as described (Chin et al., 2006).  
3.11 Micro array (mRNA expression) 
Gene expression analyses were performed using Illumina Beadarrays (HumanWG-6 
v2 Expression Beadchip) (Illumina, San Diego, CA, USA) and the Illumina system 
(www.illumina.com) according to manufacturer’s instructions at the SCIBLU 
Genomics Centre, Lund University (www.lth.se/sciblu). Illumina gene expression 
data was loaded into the Beadstudio v3 software (Illumina). Here, data was 
normalised using the cubic spine method. Normalised gene expression data was then 
exported, and only features with a detection p-value of <0.01 in at least 80% of the 
samples were used in further analyses. Next, data was loaded into MeV v4 (Saeed et 
al., 2003) where it was log2 transformed and mean centred across assays. 
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4. Summary of results 
Our main results may be summarized as follows:  
In paper I we showed that metastatic melanoma patients could be classified into 
four separate groups based on hierarchical analyses of gene expression; The four 
subtypes were named (1) high-immune response, (2) proliferative, (3) pigmentation 
and (4) normal-like, as reflected by the set of genes characteristic of each group. 
Importantly, this classification gives prognostic information, thus the patients with 
expression of proliferative genes displayed an inferior survival to the others, and 
tumours from these patients also harboured homozygote CDKN2A deletions. Low 
expression of a predefined gene set associated with B and T-cell activity was 
significantly associated to poor outcome.  
In paper II, for the first time, to our knowledge we were able to identify a predictor 
for the standard treatment of metastatic melanoma. MGMT expression was associated 
with disease stabilisation on DTIC treatment, and this marker also proved as a 
significant biomarker regarding overall survival as well as time to progression. 
Although MGMT methylation was associated with MGMT expression, MGMT 
methylation was not associated with clinical parameters, suggesting other regulation 
mechanisms of MGMT expression than methylation. In mulitivariate analyses, both 
MGMT expression and the old prognostic marker p16INK4a proved to be independent 
factors in relation to overall survival, also when Breslow thickness and serum lactate 
dehydrogenase (LDH) were included. The observed correlation between Breslow 
thickness and MGMT expression further suggests a biological link to this 
histopathological measure other than tumour load.   
In paper III, we were able to identify novel alternative splicing of BRAF, and 
expression of these splices corresponded to objective response to dacarbazine 
treatment. These splices were mostly seen in tumours wt in BRAF. Our findings were 
supported by in vitro studies of melanoma cell lines where knockdown of BRAF wild 
type for codon 600 displayed apoptosis in 30% of melanoma cells after DTIC 
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incubation whereas knockdown in mutated BRAF V600E did not respond to DTIC 
incubation.  
Lastly, in paper IV, we identified aberrations in the p53 pathway, including p53, 
MDM2 and p14ARF to predict reduced overall survival in our cohort when 
comparison was made between tumours with no or minor alterations in this pathway 
and tumours with major alterations. There was no correlation between mutational 
status and outcome when looking at the single genes in the pathway. In addition, 
when combining expression levels of p16INK4a to the analysis, a distinct group with 
no major alterations in the p53 pathway and high p16INK4a levels showed a 
significant better prognosis than the other patients. 
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5. Discussion
The main strength of this thesis is that the patient inclusion, tissue sampling and 
follow up were done in a prospective, consecutive manner in a single institution. In 
that way, bias in patient selection is excluded. Although tissue sampling and most of 
the laboratory analyses were performed by the undersigned who also participated in 
the collection of the clinical data, response and survival data were not matched with 
the laboratory findings until the follow up was closed (May 09). In that way, the 
investigator was blinded to the clinical data during the laboratory analyses.  
Results from nucleic acids, DNA and RNA analyses have been presented in this 
thesis. The genes we have analysed are all genes coding for enzymes in cellular 
signal transduction pathways. One might advocate that immunhistochemistry or 
enzyme activity testing would be more appropriate than gene analysing. However, 
enzyme activity testing is difficult to perform in patient tissue due to low sample 
volume (Tru cut biopsies), and immunehistochemistry/Western Blots are semi-
quantitative measurements. A positive immunehistochemistry (IHC) does not mean 
that protein function is normal. For instance, a single nucleotide mutation that does 
not interfere with protein folding or binding to the specific antibody used is not 
detected, although it could cause an impairment or loss in enzyme function. Yet, in 
paper I, we have included IHC analyses, and in paper III we have performed Western 
Blots from cell cultures to confirm our findings in RNA analyses. 
We have not performed micro-dissection of tumour tissue to ensure that the tissue 
analysed really is tumour cells and not supporting, non-tumour cells like fibroblasts, 
endothelium cells and white blood cells. Indeed, in paper I the main finding is that 
expression of immune response genes in the tumour is caused by infiltration of CD3 
(T-cells) and CD20 (B-cells) positive white blood cells and not expression of these 
genes in by the actual tumour cells. Regarding molecular findings in paper II-IV, at 
least in relation to mutation screening, infiltration of non-tumour cells conceals single 
nucleotide mutations rather than over-estimates them when sequencing is performed. 
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Therefore, the presence of non-tumour cells in the tissue analysed results in less 
sensitivity but does not reduce specificity in mutation screening.  
Using array based mRNA expression, we were able to differentiate our patient 
population into four different groups with different prognosis Paper I. This 
differentiation was validated in an external set of metastatic melanoma patients 
(Bogunovic et al., 2009) with the same difference in prognosis between the groups. 
Also, it was confirmed in an internal dataset of 20 patients our own protocol initially 
excluded for this analysis due to small amount of tissue available for the aCGH 
analyses. However, for the microarray analyses the tissue was sufficient, but the 
number of patients was to low to validate the prognostic difference.  
One of the problems we encountered in this study was the unfortunate low clinical 
response rate to DTIC therapy. In our cohort, only 5% responded objectively to DTIC 
monotherapy treatment. Although response rates up to 20% on DTIC has been 
reported (Lui et al., 2007), response rates differ greatly, and a response rate of 10% to 
DTIC is not uncommon (Eggermont and Kirkwood, 2004). This low response rate 
made it statistically difficult to identify biomarkers predicting response. Therefore, 
regarding the predictive factors, MGMT and BRAF (Paper II and III) splicing one 
might argue that these factors are of little value, given the fact that the objective 
response rate to dacarbazine in general is so low. Still, dacarbazine (and 
temozolomide) is the best treatment available today, even though not much superior 
to observation alone. In the MGMT paper (Paper II), we also included stable disease 
as good response which is quite common when evaluating response in melanoma 
treatment. 
The novel splice variants of BRAF detected in paper III are hypothesised to reduce 
BRAF function in a dominant negative fashion. Although expression of splice 
variants of tumour suppressor genes and oncogenes are found in tumours, and they 
have proven carcinogenic in experimental systems, the biologic relevance of splice 
variants in tumours is still controversial (Korner and Miller, 2009). In our paper, we 
were able to identify these splice variants, and there seems to be a correlation to 
BRAF V600E mutation status and objective response to DTIC treatment. Whether or 
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not the isoforms without the kinase domain have a dominant, negative effect on 
normal BRAF is not shown by our experiments. Still, we were able to prove BRAF 
link to DTIC by senthesizing melanoma cell line wt for BRAF codon 600 to DTIC 
with BRAF knockdown whereas a mutated BRAF V600E could not be senthesized to 
this treatment.  
Our identification of alterations in the p53 pathway (Paper IV) to correlate to 
overall survival in melanoma, contrasting former studies, emphasises this pathway’s 
importance in melanoma regarding biological aggressiveness. Whether the survival 
benefit of not having disturbances in this pathway was influenced by DTIC treatment 
or not is a difficult question. Although alterations did not relate to response to 
treatment significantly in our cohort, there might be some effect, and therefore a 
treatment contribution to survival benefits is possible. Still, we believe that the 
identified correlation between the p53 pathway and survival reflects tumour biology 
and not treatment. Of course, a similar analysis in an untreated patient cohort would 
answer this question, but to include patients to this study would be difficult. Although 
the treatment results are poor, most patients will try available treatment.  
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6. Future perspectives 
The identification of four distinct tumour-classes based on microarrays from biopsies 
of metastatic melanoma opens up for selectively offering novel, experimental drugs, 
like immune stimulating agents to subgroups of patients based on different predictive 
factors in future studies. So far, these new regimes have not been able to prove their 
superiority to standard treatment, at least in Phase III trials, and by offering this 
treatment to the subclasses of melanoma patients identified in our work in clinical 
studies, these regimes might show improved response rates. Performing microarray 
analysis has not become standard in medical laboratories and still remains a research 
tool. Likewise handling of the biopsies to preserve RNA for such analysis will 
require a change in clinical protocols. An ideal substitute for microarray analysis 
would therefore be an immunhistochemical (IHC) analysis that correlates thoroughly 
to our classification. We were able to correlate the microarray findings to IHC 
staining but there was not complete overlap, and further search for such ideal IHC 
analysis are warranted. Further, as RT-PCR techniques become more sophisticated 
one might hope that methods extracting RNA from formalin fixated biopsies might 
be sufficient for analyses using only fragments of RNA as substrates in predefined 
immune genes.   
Recently, ipilimumab, T-cell activator proved survival benefit in advanced 
melanoma (Hodi et al., 2010; O'Day et al., 2010). This is in concert with our findings 
that T-cell activation is an important anti-tumour mechanism and target in metastatic 
melanoma. Therefore, a trial that tested responses in different groups after our 
classification of metastatic melanoma would be of importance. Whether this drug 
could further potent anti-tumour activity in patients already harbouring T-cell 
activation in their metastatic deposits or if patients without this activation have a 
better potential for ipilimumab treatment is not clear. If all the responders are in the 
immune activated group, this treatment can be offered to these patients selectively 
with even better responses than found by Hodi et al.  
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The identification of MGMT expression as a positive predictor for stabilisation of 
the disease on DTIC treatment is one of the findings that add to the development of a 
tailored medication of this disease on the basis of biomarker status. After validation 
of our findings, DTIC treatment can than be offered selectively to patients expressing 
low MGMT levels in metastatic deposits, thereby avoiding ineffective treatment to 
patients with high MGMT expression. Again, to use the analyse tools provided in this 
paper, RNA has to be harvested from metastatic tumours for analyses, and of course, 
IHC substitute would be easier to be incorporated in clinical practice.  
The discovery of novel alternative BRAF splices variants further emphasises 
BRAF’s importance in melanoma and also in prediction of chemosensitivity. Further 
clinical follow up studies are warranted, and the functional role of each isoform needs 
to be tested in vitro to prove their inhibitory effect on the wild type isoforms. The 
introduction of new inhibitors in this pathway, with improved response rates in early 
studies elucidates our findings, and it will be interesting to test out this treatment in 
relation to BRAF mutational/splicing status. One of the most exciting compounds in 
this aspect is the new drug, PLX 4032, which has shown promising results in phase I 
study with high objective response rate of the BRAF 600 mutated patients receiving 
the drug (Flaherty et al., 2009). Another compound which selectively inhibits BRAF 
600E has shown promising response rates in a Phase I/II trial (Kefford et al., 2010).  
Our discovery of the p53 pathway to be of importance in melanoma at least in 
respect to overall survival further adds to the prognostic implication of doing 
molecular testing in cancer. Although former studies have shown little importance of 
p53 in melanoma, analyses of other signal molecules in the p53 cascade question this 
theory. Still, we were not able to associate this finding to chemoresistance in this 
study, but in another cohort with better response rates such correlation may become 
significant. 
The work presented in this thesis provides better knowledge about the molecular 
diversity in metastatic melanoma patients, both regarding response to treatment and 
survival. This is a field that has been poorly explored; work in the past has been 
focused on primary melanoma and cell lines from primary and metastatic spread. 
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There are few other cohorts on metastatic melanoma analysing molecular biomarkers’ 
correlation to response to treatment and survival, and our findings could be adapted 
into clinical treatment after validation and some adjustments. Therefore, the results 
are crucial for tailoring existing treatment and will also serve as a guide in offering 
new, targeted therapy and immune-stimulating therapy to the right patient groups.   
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